The Indian Health Service Response to the Opioid Crisis
IHS National Committee on Heroin, Opioids, and Pain Efforts (HOPE Committee) & Health Information Management

CDR Katie Johnson, PharmD, MHIIM
EHR Integrated Care Coordinator, NPAIHB
Technical Assistance Workgroup Lead, HOPE Committee

November 2019
US drug overdose deaths: Opioid categories

SOURCE: NCHS, National Vital Statistics System, Mortality
Opioid Overdose Death Rates

• CDC data indicates that American Indians and Alaska Natives (AI/AN) had the second highest overdose death from rates from all opioids in 2017 (15.7 deaths/100,000 population) among racial/ethnic groups in the US

• AI/AN had the highest overdose death rate for prescription opioids (7.2)

• AI/AN had the second highest overdose death rates from heroin (5.2)

• AI/AN had the third highest from synthetic opioids (6.5)

• The overall rate of overdose deaths for AI/AN has increased by 13% between 2015-2017

National Committee on Heroin, Opioids, and Pain Efforts (HOPE)

- IHS Committee created in March 2017
- Evolved out of the Prescription Drug Abuse Workgroup
- Membership: physicians, pharmacists, behavioral health providers, nurses, APNs, physical therapists, epidemiologists, and informatics
- Goals:
  - Promote appropriate and effective pain management
  - Reduce overdose deaths from heroin and prescription opioid misuse
  - Improve access to culturally appropriate treatment
HHS 5-POINT STRATEGY
TO COMBAT THE OPIOIDS CRISIS

1. Better addiction prevention, treatment, and recovery services
2. Better data
3. Better pain management
4. Better targeting of overdose reversing drugs
5. Better research

HHS.GOV/OPIOIDS
OFFICE OF INSPECTOR GENERAL Report

IHS NEEDS TO IMPROVE OVERSIGHT OF ITS HOSPITALS’ OPIOID PRESCRIBING AND DISPENSING PRACTICES AND CONSIDER CENTRALIZING ITS INFORMATION TECHNOLOGY FUNCTIONS

https://oig.hhs.gov/oas/reports/region18/181711400.pdf
Attempts to Standardize Chronic Pain Documentation

• Chronic Pain Template
  ◦ Released and under revision—purpose to assist with QA for IHM Part 3, Chapter 30

• PDMP Documentation—Released

• Best Practice Recommendations
  ◦ Functional status assessment:
    ◦ CPT 1502F: Patient queried about pain and pain interference with function using a valid and reliable instrument
  ◦ Identifying Patients on Chronic Opioid Therapy:
    ◦ ICD10 code Z79.891 (supplemental chronic diagnosis) :
      Long-term current use of opioid analgesic drug

• Patient Agreement and Informed Consent samples on https://www.ihs.gov/painmanagement/treatmentplanning/informedconsent/
Chronic Pain Template

• IHS Chapter 30 - [https://www.ihs.gov/ihm/pic/part-3/p3c30/#3-30.1](https://www.ihs.gov/ihm/pic/part-3/p3c30/#3-30.1)
  ◦ Outlines some documentation requirements for patients on chronic opioid therapy

• TIU Note template needed to assist providers in meeting these requirements
  ◦ Version 1 released
  ◦ Version 2 out for testing/feedback
  ◦ A version for follow up visits in progress
  ◦ Meant to be used as is or as a starting point for modifications
  ◦ Just a tool

Live Demo
PDMP Documentation

• IHS Chapter 30 and 32 address PDMP use
• Record of PDMP access is with PDMP vendor/State
• Documentation via EHR through use of Patient Education Code
  ◦ (see “How To” document)
• Ability to retrieve through a FileMan report
• Live Demo
Code Recommendations

• Best Practice Recommendations – joint efforts with HOPE and National HIM

  ◦ Functional status assessment:
    ◦ CPT 1502F: Patient queried about pain and pain interference with function using a valid and reliable instrument

  ◦ Identifying Patients on Chronic Opioid Therapy:
    ◦ ICD10 code Z79.891 (supplemental chronic diagnosis): Long-term current use of opioid analgesic drug
    ◦ SNOMED mapped is: 452271000124108
Next Steps

• Outside prescription note template - released

• UDS: recommendations pending-- ‘therapeutic drug monitoring’ SNOMED


• 42CFR Part 2

• NEW CRS SUD measures for pregnant women and women of child-bearing age—goal is to increase screening
  ◦ 4PS Screen

• Chronic Opioid Therapy Reminders
GPRA Developmental Measure


- Substance Use Disorder (SUD) in Women of Childbearing Age

- Substance use disorder screen CRS will search for screenings in the following order:
  1) screen with a positive result followed by a BNI closest to the date of the screen;
  2) screen with a positive result with no BNI;
  3) screen with a negative result.

- Substance use disorder screen defined as any of the following:
  - Health Factor 4PS
  - Measurement in PCC of DAST-10
Clinical Reminders

• Phoenix Indian Medical Center – has some currently in place

• HOPE Committee working to add to and make this base idea more universal so that any site can implement

• Clinical Reminders and dialogs to address:
  ◦ Consistently updated Treatment Agreements/Plan
  ◦ Urine Drug Screens
  ◦ Functional Status Assessment
  ◦ PDMP check documentation
  ◦ Narcan kit dispensing
  ◦ Patient education on chronic opioids
Ideas for Training

• Training provider/prescribers on these best practices
  ◦ Include coding as part of that training

• Written training materials focused on HIM
  ◦ Tip sheets
Stay Connected

- IHS Websites
  - MAIN Website: [www.ihs.gov/opioids](http://www.ihs.gov/opioids)
  - HOPE Committee Newsletters
  - HOPE Committee Listserv
HOPE Committee

- Officers:
  - Chair- CAPT Cindy Gunderson, PharmD- Cynthia.Gunderson@ihs.gov
  - Vice Chair- Julianna Reece, MD, MPH, MBA- Julianna.Reece@ihs.gov
  - Secretary- LCDR Kristin Allmaras, PharmD- KAllmaras@SouthcentralFoundation.com

- Prescriber Support: Chris Fore, PhD; CAPT Tarri Randall,

- Medication Assisted Treatment: CDR Kailee Fretland, PharmD

- Harm Reduction: CDR Hillary Duvivier, PharmD; CAPT Holly Billie, MPH; LCDR Samantha Gustafson, PharmD

- Perinatal Substance Use: LT Sherry Daker, PharmD

- Metrics: CAPT Thomas Weiser, MD; Tamara James, PhD

- Technical Assistance: CDR Tyler Lannoye, PharmD; CDR Katie Johnson, PharmD

- Website & Communications: LT Nicholas Cushman, PharmD

- Changing attitudes, beliefs, and perceptions: CAPT Joel Beckstead, PhD

- Executive Leadership Committee: RADM Michael Toedt, MD, Marcy Ronyak, PhD, CAPT Kevin Brooks, PharmD